drug
(atazanavir sulfate + cobicistat)
Marketedupdated 3mo agoby Bristol-Myers Squibb Co
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 3, 2029
~3.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Oct 6, 2032formulationUS 10039718
- Sep 3, 2029compositionUS 81483743.1y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 8m ago
Found something off?
comments(0)
5-min edit window · permanent after that